|
|||
|
Eight-Year Experience With Botulinum Toxin Type-A Injections for the Treatment of Nonneurogenic Overactive Bladder: Are Repeated Injections Worthwhile?
Shannon HK Kim, David Habashy, Sana Pathan, Vincent Tse, Ruth Collins, Lewis Chan
Int Neurourol J. 2016;20(1):40-46. Published online 2016 Mar 16
DOI: https://doi.org/10.5213/inj.1630450.225 |
|||
|
Citations to this article as recorded by  Variation in the Definitions of Urinary Retention in Studies of Intravesical Botulinum Toxin for Idiopathic Overactive Bladder: A Narrative Systematic Review
Stephanie Stavrou, Jessica A. Paynter, Thomas Carins, Kirby R. Qin, Janelle Brennan
Neurourology and Urodynamics.2025;[Epub] CrossRef Intravesical Injection of Botulinum Toxin Type A in Patients with Refractory Overactive Bladder—Results between Young and Elderly Populations, and Factors Associated with Unfavorable Outcomes
Yin-Chien Ou, Yao-Lin Kao, Yi-Hui Ho, Kuan-Yu Wu, Hann-Chorng Kuo
Toxins.2023; 15(2): 95. CrossRef Bladder Dysfunction in Older Adults: The Botulinum Toxin Option
Yao-Lin Kao, Yin-Chien Ou, Hann-Chorng Kuo
Drugs & Aging.2022; 39(6): 401. CrossRef Effect of mesenchymal stem cells on induced skeletal muscle chemodenervation atrophy in adult male albino rats
Azza S. Shehata, Nabila M. Al-Ghonemy, Samah M. Ahmed, Samar R. Mohamed
The International Journal of Biochemistry & Cell Biology.2017; 85: 135. CrossRef
|
